Approval BlogMedical CommunicationsOncology Updates Tisagenlecleucel for Patients with Relapsed or Refractory Large B-cell Lymphoma
Approval BlogMedical CommunicationsOncology Updates Dabrafenib and Trametinib for Adjuvant Treatment of BRAF V600E/K-Positive Melanoma
FEATURED CONSULTINGMedical Communications What are the biggest concerns manufacturers have about the Sunshine Act?
FEATURED BLOGSMedical Communications Will the Sunshine Act eliminate bias from the US healthcare system?
Approval BlogMedical CommunicationsOncology Updates Osimertinib for the Frontline Treatment of EGFR-mutant NSCLC
Approval BlogMedical CommunicationsOncology Updates Combination of Nivolumab Plus Ipilimumab for Frontline Treatment of Renal Cell Carcinoma
Approval BlogMedical CommunicationsOncology Updates Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Approval BlogMedical CommunicationsOncology Updates Blinatumomab for Patients with MRD-positive B-cell Precursor ALL
Approval BlogMedical CommunicationsOncology Updates Nilotinib Receives FDA-approval to Treat Pediatric Patients with Chronic Phase CML